Abstract

Histologic transformation of Waldenström macroglobulinemia (HT-WM) carries a poor prognosis with standard treatments. Here, we report the first series of HT-WM treated with chimeric antigen receptor T cells showing a high efficacy and no unexpected toxicity.

Subjects:
Clinical Trials and Observations, Immunobiology and Immunotherapy, Lymphoid Neoplasia
1.
Durot
E
,
Tomowiak
C
,
Michallet
AS
, et al.
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome: a multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)
.
Br J Haematol
.
2017
;
179
(
3
):
439
-
448
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Zanwar
S
,
Abeykoon
JP
,
Durot
E
, et al.
Impact of MYD88L265P mutation status on histological transformation of Waldenström macroglobulinemia
.
Am J Hematol
.
2020
;
95
(
3
):
274
-
281
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Castillo
JJ
,
Gustine
J
,
Meid
K
,
Dubeau
T
,
Hunter
ZR
,
Treon
SP
.
Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia
.
Am J Hematol
.
2016
;
91
(
10
):
1032
-
1035
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Durot
E
,
Kanagaratnam
L
,
Zanwar
S
, et al.
A prognostic index predicting survival in transformed Waldenström macroglobulinemia
.
Haematologica
.
2021
;
106
(
11
):
2940
-
2946
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Durot
E
,
Kanagaratnam
L
,
Zanwar
S
, et al.
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia
.
Blood Adv
.
2022
;
6
(
12
):
3655
-
3658
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Boardman
AP
,
Salles
G
.
CAR T-cell therapy in large B cell lymphoma
.
Hematol Oncol
.
2023
;
41
(
suppl 1
):
112
-
118
.
Google Scholar
PubMed
 
7.
Abramson
JS
,
Palomba
ML
,
Gordon
LI
, et al.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
.
Lancet
.
2020
;
396
(
10254
):
839
-
852
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Bansal
R
,
Jurcic
JG
,
Sawas
A
,
Mapara
MY
,
Reshef
R
.
Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia
.
Leuk Lymphoma
.
2020
;
61
(
2
):
465
-
468
.
Google Scholar
Crossref
Search ADS
PubMed
 
9.
Cheson
BD
,
Fisher
RI
,
Barrington
SF
, et al.
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
.
J Clin Oncol
.
2014
;
32
(
27
):
3059
-
3068
.
Google Scholar
Crossref
Search ADS
 
10.
Locke
FL
,
Ghobadi
A
,
Jacobson
CA
, et al.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
.
Lancet Oncol
.
2019
;
20
(
1
):
31
-
42
.
Google Scholar
Crossref
Search ADS
PubMed
 
11.
Neelapu
SS
,
Locke
FL
,
Bartlett
NL
, et al.
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
.
Blood Adv
.
2021
;
5
(
20
):
4149
-
4155
.
Google Scholar
Crossref
Search ADS
PubMed
 
12.
Schuster
SJ
,
Bishop
MR
,
Tam
CS
, et al.
Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
.
N Engl J Med
.
2019
;
380
(
1
):
45
-
56
.
Google Scholar
Crossref
Search ADS
 
13.
Westin
JR
,
Kersten
MJ
,
Salles
G
, et al.
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials
.
Am J Hematol
.
2021
;
96
(
10
):
1295
-
1312
.
Google Scholar
Crossref
Search ADS
PubMed
 
14.
Kambhampati
S
,
Merryman
RW
,
Wang
Y
, et al.
Real-world outcomes of CD19 CAR T cell therapy in adult patients with relapsed refractory transformed indolent lymphoma [abstract]
.
Blood
.
2023
;
142
(
suppl 1
):
3511
.
Google Scholar
 
15.
Rivas-Delgado
A
,
Luttwak
E
,
Drill
E
, et al.
Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy [abstract]
.
Blood
.
2023
;
142
(
suppl 1
):
4888
.
Google Scholar
 
16.
Nydegger
A
,
Novak
U
,
Kronig
MN
, et al.
Transformed lymphoma is associated with a favorable response to CAR-T-cell treatment in DLBCL patients
.
Cancers
.
2021
;
13
(
23
):
6073
.
Google Scholar
Crossref
Search ADS
PubMed
 
17.
Bensaber
H
,
Bachy
E
,
Beauvais
D
, et al.
Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: a Lysa study from the Descar-T registry [abstract]
.
Blood
.
2022
;
140
(
suppl 1
):
3803
-
3804
.
Google Scholar
 
18.
Shadman
M
,
Frigault
MJ
,
Foley
SR
, et al.
Real-world tisagenlecleucel outcomes in Richter-transformed chronic lymphocytic leukemia: a Center for International Blood & Marrow Transplant Research (CIBMTR) analysis [abstract]
.
Blood
.
2023
;
142
(
suppl 1
):
3497
.
Google Scholar
 
19.
Kittai
AS
,
Bond
DA
,
Huang
Y
, et al.
Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an international multicenter, retrospective study
.
J Clin Oncol
.
2024
;
29
:
JCO2400033
.
Google Scholar
 
© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
Sign in via your Institution